Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.7
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 20513427
Qiao M, et al. (2010) Mst1 is an interacting protein that mediates PHLPPs' induced apoptosis. Mol Cell 38, 512-23 20513427
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  brain cancer, glioblastoma, glioma, breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), BT-474 (breast cell), COLO-357 (pancreatic), HMEC (endothelial), PANC-1 (pancreatic), U87MG (glial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

T202-p - ERK1 (human)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): T202‑p, ERK1 iso2 (human): T202‑p, ERK1 iso3 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control
PHLPP2 (human) no change compared to control
MST1 (human), PHLPP (human) no change compared to control Mst1 inactive kinase no change
MST1 (human), PHLPP2 (human) no change compared to control Mst2 inactive kinase no change

Y204-p - ERK1 (human)
Modsite: HtGFLtEyVAtRWyr SwissProt Entrez-Gene
Orthologous residues
ERK1 (human): Y204‑p, ERK1 iso2 (human): Y204‑p, ERK1 iso3 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control
PHLPP2 (human) no change compared to control
MST1 (human), PHLPP (human) no change compared to control Mst1 inactive kinase no change
MST1 (human), PHLPP2 (human) no change compared to control Mst2 inactive kinase no change

S256-p - FOXO1A (human)
Modsite: sPrRrAAsMDNNskF SwissProt Entrez-Gene
Orthologous residues
FOXO1A (human): S256‑p, FOXO1A (mouse): S253‑p, FOXO1A (rat): S250‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

S9-p - GSK3B (human)
Modsite: SGRPRttsFAEsCkP SwissProt Entrez-Gene
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S9‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

T183-p - JNK1 (human)
Modsite: AGtsFMMtPyVVtRY SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): T183‑p, JNK1 iso2 (human): T183‑p, JNK1 iso3 (human): T183‑p, JNK1 (mouse): T183‑p, JNK1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) increase PHLPP siRNA decreases
PHLPP2 (human) increase PHLPP2 siRNA decreases
PHLPP (human), PHLPP2 (human) increase PHLPP, PHLPP2 siRNA decreases
MST1 (human), PHLPP (human) increase Inactive MST1 decreases
MST1 (human), PHLPP2 (human) increase inactive Mst1 decreases

Y185-p - JNK1 (human)
Modsite: tsFMMtPyVVtRYYR SwissProt Entrez-Gene
Orthologous residues
JNK1 (human): Y185‑p, JNK1 iso2 (human): Y185‑p, JNK1 iso3 (human): Y185‑p, JNK1 (mouse): Y185‑p, JNK1 (rat): Y185‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) increase PHLPP siRNA decreases
PHLPP2 (human) increase PHLPP2 siRNA decreases
PHLPP (human), PHLPP2 (human) increase PHLPP, PHLPP2 siRNA decreases
MST1 (human), PHLPP (human) increase Inactive MST1 decreases
MST1 (human), PHLPP2 (human) increase inactive Mst1 decreases

S218-p - MEK1 (human)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S218‑p, MEK1 iso2 (human): S192‑p, MEK1 (mouse): S218‑p, MEK1 (rat): S218‑p, MEK1 (rabbit): S218‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

S222-p - MEK1 (human)
Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene
Orthologous residues
MEK1 (human): S222‑p, MEK1 iso2 (human): S196‑p, MEK1 (mouse): S222‑p, MEK1 (rat): S222‑p, MEK1 (rabbit): S222‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

S222-p - MEK2 (human)
Modsite: VsGQLIDsMANsFVG SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S222‑p, MEK2 (mouse): S222‑p, MEK2 (rat): S222‑p, MEK2 (chicken): S220‑p, MEK2 (cow): S222‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

S226-p - MEK2 (human)
Modsite: LIDsMANsFVGtRSY SwissProt Entrez-Gene
Orthologous residues
MEK2 (human): S226‑p, MEK2 (mouse): S226‑p, MEK2 (rat): S226‑p, MEK2 (chicken): S224‑p, MEK2 (cow): S226‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

T183-p - MST1 (human)
Modsite: DtMAkRNtVIGTPFW SwissProt Entrez-Gene
Orthologous residues
MST1 (human): T183‑p, MST1 iso2 (human): T183‑p, MST1 (mouse): T183‑p, MST1 (rat): T183‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) increase PHLPP siRNA decreases
PHLPP2 (human) increase PHLPP2 siRNA decreases
PHLPP (human), PHLPP2 (human) increase PHLPP, PHLPP2 siRNA decreases
MST1 (human), PHLPP (human) increase Inactive MST1 decreases
MST1 (human), PHLPP2 (human) increase inactive Mst1 decreases

T387-p - MST1 (human)
Modsite: tMKRRDEtMQPAKPs SwissProt Entrez-Gene
Orthologous residues
MST1 (human): T387‑p, MST1 iso2 (human): T387‑p, MST1 (mouse): T387‑p, MST1 (rat): T387‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
PHOSPHATASE PHLPP (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
PHOSPHATASE PHLPP (human) phospho-antibody, co-immunoprecipitation, transfection of wild-type enzyme
Downstream Regulation
Effect of modification (function):  enzymatic activity, induced
Effect of modification (process):  apoptosis, altered

T180-p - P38A (human)
Modsite: RHtDDEMtGyVAtRW SwissProt Entrez-Gene
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p, P38A (salmonid): T181‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) increase PHLPP siRNA decreases
PHLPP2 (human) increase PHLPP2 siRNA decreases
PHLPP (human), PHLPP2 (human) increase PHLPP, PHLPP2 siRNA decreases
MST1 (human), PHLPP (human) increase Inactive MST1 decreases
MST1 (human), PHLPP2 (human) increase inactive Mst1 decreases

Y182-p - P38A (human)
Modsite: tDDEMtGyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p, P38A (salmonid): Y183‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) increase PHLPP siRNA decreases
PHLPP2 (human) increase PHLPP2 siRNA decreases
PHLPP (human), PHLPP2 (human) increase PHLPP, PHLPP2 siRNA decreases
MST1 (human), PHLPP (human) increase Inactive MST1 decreases
MST1 (human), PHLPP2 (human) increase inactive Mst1 decreases

S661-p - PKCB (human)
Modsite: QNEFAGFsYTNPEFV SwissProt Entrez-Gene
Orthologous residues
PKCB (human): S661‑p, PKCB iso2 (human): S660‑p, PKCB (mouse): S661‑p, PKCB iso2 (mouse): S660‑p, PKCB (rat): S661‑p, PKCB iso2 (rat): S660‑p, PKCB (cow): S660‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control except decrease in 21T-MT2 cells
PHLPP2 (human) no change compared to control except decrease in 21T-MT2 cells

T183-p - ERK2 (mouse)
Modsite: HDHtGFLtEyVAtRW SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p, ERK2 (cow): T185‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control
PHLPP2 (human) no change compared to control
MST1 (human), PHLPP (human) no change compared to control Mst1 inactive kinase no change
MST1 (human), PHLPP2 (human) no change compared to control Mst2 inactive kinase no change

Y185-p - ERK2 (mouse)
Modsite: HtGFLtEyVAtRWYR SwissProt Entrez-Gene
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p, ERK2 (cow): Y187‑p
Characterization
Methods used to characterize site in vivo immunoprecipitation, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  21T (breast cell), 293T (epithelial), PANC-1 (pancreatic)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PHLPP (human) no change compared to control
PHLPP2 (human) no change compared to control
MST1 (human), PHLPP (human) no change compared to control Mst1 inactive kinase no change
MST1 (human), PHLPP2 (human) no change compared to control Mst2 inactive kinase no change